New Funding Announcement
US National Institute of Allergy and Infectious Diseases (NIAID) Notice of Special Interest (NOSI)—Advancing Research Needed To Develop a Universal Influenza Vaccine: the purpose of the funding [...]
Tracking progress in universal influenza vaccine development
Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal [...]
To avoid the next coronavirus, we need a vaccine before the outbreak
“As the number of people infected with the coronavirus (which causes the coronavirus disease 2019, or COVID-19) continues to rise, the full extent and severity of this outbreak still [...]
To finally develop a universal flu vaccine, innovative science and financing must combine forces
“An unwelcome visitor during the holiday season has returned: influenza. As of today, six children have already fallen victim to the disease. And, as the Centers for Disease Control and [...]
European Investment Bank (EIB) Extends Financing Agreement to €24 Million Total in Support of BiondVax’s Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
“JERUSALEM, April 22, 2019 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), announced today that the Management Committee of the European Investment Bank (EIB) agreed to [...]
NIH begins first-in-human trial of a universal influenza vaccine candidate
“The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in [...]
Investigators Exploring Microneedle Patch As Universal Influenza Vaccine Candidate
“Work to develop a universal flu vaccine using a microneedle patch will continue at Georgia State University’s Institute for Biomedical Sciences with a $3.86 million grant from the National [...]
Bill enhances universal flu vaccine investment
“Sen. Edward J. Markey (D-MA) and Rep. Rosa DeLauro (D-CT) recently reintroduced a measure designed to bolster the financial support for a universal influenza vaccine protecting against [...]
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus
“FluGen, Inc. today announced preliminary data from a human challenge trial with its investigational intranasal M2SR vaccine showing, for the first time, protection against a highly [...]
Influenza: are we ready?
“When 100 passengers on a flight from Dubai to New York in September 2018 fell ill with respiratory symptoms, health officials were concerned that they might be carrying a serious [...]
